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Introduction
The term “hereditary cancer” refers to cancers associ-
ated with specific germ-line mutations in highly penetrant
genes which are inherited as a Mendelian trait, whether
through an oncogene, a tumor suppressor gene, or a DNA re-
pair gene. Since the first association between germ-line mu-
tations and hereditary predisposition for particular cancer
types has been found in the mid of 90-ties, investigations
pointed out a variety of tumor types with inherited predispo-
sition to a high or moderate/low risk  for development of dis-
ease (melanoma, gastric cancer, MEN I, MEN II, hereditary
nonpolyposis colon cancer, etc) 
1–4. Data that hereditary pre-
disposition, recognized by family clustering, has been found
for the arising number of cancer types,  together with intro-
ducing of screening for the mutations in responsible genes,
makes different insight into cancer prevention and manage-
ment of patients with malignant disease.
Breast cancer is the most frequent malignant tumor in
females in Serbia. The incidence can be described with more
than 4,000 newly diagnosed cases per year 
5, 6. Unfortu-
nately, incidence and mortality trends show permanent in-
crement in the few last years. Breast cancer can occur as spo-
radic, familial and hereditary. The majority of breast cancers
are recognized as sporadic in patients with no cancer history
in the family. The incidence of sporadic breast cancer rises in
women over 50 years old. Minorities of breast and/or ovarian
cancer patients (up to 5% to 10%) have a striking family
history, suggestive of Mendelian autosomal dominant in-
heritance. An additional 20% of breast cancer cases are con-
sidered as familial describing situation with at least two can-
cer cases in extended family. In hereditary form of disease
one of the two alleles of the gene responsible for the disease
is altered by germ-line mutation. The off-spring of the muta-
tion carriers has 50% chance of inheriting a mutant allele
from either parent. The most common variant of hereditary
breast cancer (HBC) is the appearance of breast as well as
ovarian cancer cases in the same family (HBOC). The disease
can also occur as site-specific breast or ovarian cancer. Other
tumor types such as pancreatic cancer, Fallopian tube carci-
noma, melanoma or prostate cancer in men can be commonly
present in families with hereditary breast cancer 
7–9.
Characteristics and functions of BRCA 1/2 genes
Discovery of the association between breast and ovarian
cancer and BRCA1 (in 1994) and BRCA2 (in 1995) genes
have made it possible to screen women for genetic predispo-
sition to develop either one or both of these diseases 
7.
BRCA1 and BRCA2 genes are highly, but not completely
penetrant genes (about 80%). So far, more than 20 genes of
low to medium penetrance that can modify the pentrance of
BRCA1/2 genes in carriers of mutations (modifier genes), in
that way modifying risk for hereditary disease, have been
identified 
10, 11.
BRCA1 and BRCA2 genes are classified as tumor sup-
pressor genes. Both genes are large – BRCA1 has 22 and
BRCA2 26 coding exons. For both genes exon 1 is noncod-
ing, and both have unusually large exon 11. BRCA1 gene is
located on chromosome 17q21 while BRCA2 is located on
chromosome 13q12. BRCA1 encodes for 1863, while
BRCA2 encodes for 3418 amino acid protein product 
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tations are scattered throughout coding regions of both genes
without clustering or “hot spots” resulting in a huge number
of mutations detected in each gene – more than 1,600 in
BRCA1 and 1,900 in BRCA2 mutations have been reported
7, 8. The majority of them, but not all of them, are capable of
disrupting the function of BRCA protein product in that way
affecting the risk for malignant disease. So far, we identified
15 persons affected with BRCA1 (7 types in 11 persons) and
BRCA2 (3 types in 4 persons) deleterious mutations in Ser-
bian population. Other BRCA1/2 sequence variants (unclas-
sified and polymorphic) were also found 
12–16. Among them,
4765del20 in exon 15 of BRCA1 and 4366insTT in exon 11
of BRCA2 gene are new deleterious mutations, firstly re-
ported in our population 
16.
Concerning mutation type, about 70% of detected mu-
tations are frameshift mutations, while nonsense, as well as
missense mutations contribute with about 10% each. Besides
small changes in DNK structure such as frameshift or point
mutations, in BRCA genes are also reported large genomic
rearrangements.  Somatic BRCA1/2 mutations are rare in
sporadic breast cancer, but other mechanisms such as epige-
netic inactivation by hypermethilation of BRCA1 promotor
sequence were reported. BRCA1/2 somatic mutations are not
so rare events in sporadic ovarian cancer 
17.
BRCA1 and BRCA2 mutational spectra are population
- specific and different founder mutations are reported in dif-
ferent populations 
7, 18. Data about ethnicity is also important
since it has been shown that some ethnically isolated popu-
lations such as Ashkenazi Jews or Islanders, due to inbreed-
ing, have limited number of BRCA1/2 mutations – more than
90% of BRCA mutation carriers of Ashkenazi Jewish
women can be described with two BRCA1 (185delAG and
5382insC) and one BRCA2 (6174delT) mutations 
19, 20. In
Iceland, which is geographically isolated, there is only one
founder mutation 
21. This is the consequence of “founder ef-
fect” – some of rare mutations in small and isolated ethnic
groups may become more frequent in the next generations
due to reproductive isolation (founder mutations). All popu-
lations have their own founder mutations, but they can not be
easily recognized due to the presence of additional BRCA
variants that rose in reproductively mixed populations 
15.
But, large proportion of BRCA mutations are detected only
once – it can be said that the most of families at risk tend to
have their own mutation. Besides common, population spe-
cific and family specific mutations are detected 
16. It is ques-
tionable if all deleterious mutations have the same pene-
trance 
7. Age-dependent penetrance of different germ-line
mutations in BRCA1 genes was recently reported – the
authors concluded that different BRCA1 mutations have dis-
tinct effects that influence age of onset of breast and ovarian
cancer 
22.
BRCA1/2 protein products are implicated in a variety
of important cellular processes acting through interaction
with other molecules in signalling pathways – DNA repair,
transcriptional regulation, cell-cycle regulation and chroma-
tin remodelling (reviewed in Figure 1). BRCA1 and BRCA2
protein products are included in repair of doublestrad DNA
breaks by homologous recombination mechanism. For ex-
ample, ionizing radiation, as well as cytotoxic agents cause
DNA doublestrand breaks.
Mutations in BRCA1/2 genes, especially frameshift
mutations, cause the syntheses of proteins truncated at
various extent. Such protein product, usually lack some
domain crucial for its proper function (such as BRCT or
BRC domains in BRCA1 or BRCA2), respectively, leading
to genome instability and elevated cancer risk 
7. BRCT
domains are crucial for BRCA1 interaction with a variety
of proteins, forming complexes and enabling proper func-
tion of various important cellular processes. The fact that
about 80% of BRCA1 germline mutations result in C ter-
Fig. 1 – Schematic representation of BRCA1 and BRCA2 cellular pathways
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minus truncation that include BRCT region and lead to in-
creased predisposition for breast and/or ovarian cancer,
point out the importance of BRCT domains for BRCA1
protein function. BRCA1 protein has a highly conserved
RING domain at its amino terminus and two BRCT do-
mains at the end of its carboxyl terminus. The fact that
many clinically important mutations are located in parts of
BRCA1 gene that encode these highly conserved domains
indicates that they are very important for BRCA1 function.
The RING domain of BRCA1 mediates its association with
BRCA1-associated RING domain protein 1 (BARD1) 
23.
BRCA1–BARD1 dimer has been implicated in the mainte-
nance of genomic stability and tumor suppression through
its involvement in DNA damage signalling, DNA repair
and transcriptional regulation. BRCT domains interact with
Rb tumor suppressor gene, as well as with other proteins
associated with Rb, that are thought to be included in
chromatin remodelling processes 
24 that is required before
and after DNA repair processes.
The main function of BRCA2 protein is DNA repair.
BRCA2 protein in its structure has eight BRC repeats that
represent conserved sequence motifs of about 30 amino acids
each. BRC repeats are crucial for BRCA2 interaction with
RAD51. BRCA2, by interacting with RAD51, plays a key
role in DNA repair by homologous recombination. Lack of
any of those domains disrupts BRCA2-RAD51 interaction,
leading to DNA repair malfunction, elevating cancer risk 
7.
Lifetime risk for the development of cancer in
BRCA1/2 mutation carriers
It must be pointed out that the risk of BRCA-associated
breast and ovarian cancer is related only to epithelial malig-
nancies of both organs. As the consequence of limited pena-
trance of BRCA genes is the fact that all of BRCA1/2 muta-
tion carriers will not develop malignant disease. So far, it is
not possible to predict which of BRCA mutation carriers will
develop disease, although genetic or environmental factors
affecting penetrability of BRCA genes are intensively inves-
tigated 
25–27. Identification of BRCA1 and BRCA2 mutation
can be used only for the risk estimation. But, it is obvious
that the majority of women with inherited mutation in
BRCA1 or BRCA2 gene will develop breast and/or ovarian
cancer. Earlier estimates of lifetime risk were higher, espe-
cially if they were derived from families with a strong posi-
tive family history. Estimates of lifetime risk vary considera-
bly depending on the group studied (for instance, if cases are
selected for family history or not), type of mutations in-
cluded in study, age selected etc. For instance, for Ashkenazi
Jewish BRCA1 mutation 5382insC, which is also present in
Serbian population, lifetime risk by the age of 70 is 67% and
for ovarian cancer is 33% 
28. Generally, reported BRCA1 -
and BRCA2 - related risk estimates by the age of 70 for
breast cancer range from 45% to up to 87% – it can be said
that the risk is elevated about 5 to 8 times in comparison to
the risk for sporadic breast cancer. The risk of ovarian cancer
by the age of 70 in BRCA1 mutation carriers range from
28% to 44%, while for BRCA2 carriers estimates are lower
(from 11 to 27%) 
29. The risk for the development of ovarian
cancer is elevated about 20 times in BRCA1/2 mutation car-
riers 
29. Characteristic of BRCA-related cancer is that he-
reditary breast cancer occurs at an earlier age than the spo-
radic form of disease. Women with BRCA1/BRCA2 muta-
tion have a 33% to 50% chance to develop breast cancer be-
fore the age of 50 in comparison with general population
with the chance of 2% only 
30.
The presence of BRCA1/2 mutation elevates the risk
for bilateral breast cancer. BRCA1 mutation elevates the risk
for contralateral breast cancer up to 64% by the age of 70,
while BRCA2 mutations elevates this risk to about 50% 
31.
Besides this, elevated lifetime risk (up to 7%) for male
breast and prostate cancer (up to 20%) is mostly related to
BRCA2 mutation 
32.
Hereditary predisposition identifying
Now it is clear that with BRCA1/2 alterations all he-
reditary predisposition for breast/ovarian cancer can not be
covered. It was shown that BRCA mutations caused heredi-
tary form of the disease in families with both tumor types
clustering (breast/ovarian) (75%). In site-specific breast can-
cer the percent is lower – about 60% of female breast cancer
families are caused by BRCA1/BRCA2 mutations 
8. This
data depends on population studied. It is clear that besides
contribution of alterations of some other genes such as p53
(Li-Fraumeni syndrome), PTEN (Cowden syndrome), ATM
ataxia–telangiectasia i (mutated protein) etc., which rarely
influence hereditary predisposition to breast/ovarian cancer,
some now undefined genes will be discovered.
As major clinical benefits may occur through identify-
ing clinical risk indicators of the hereditary cancer pheno-
type, it is necessary that attention be paid to 
33: positive fam-
ily history of breast cancer, especially with early age of onset
(at least two cases of breast cancer before the age of 50 from
the same side (of family tree - about 50% of BRCA1-
associated breast cancer cases are diagnosed by age of 41);
breast cancer before the age of 35, without positive family
history; bilateral breast cancer; ovarian cancer at any age as-
sociated with positive family history of breast and/or ovarian
cancer; multiple cancers in the same person; male breast
cancer at any age; relatives of a BRCA mutation carrier;
Ashkenazi Jewish ancestry.
Genetic susceptibility testing
Hereditary breast and/or ovarian cancer belong to the
group of hereditary syndromes with a high probability of link-
age to known cancer susceptibility genes (BRCA1/BRCA2). It
is accepted that identification of mutation carriers carry medical
benefit, although due to limited penetrance of BRCA genes it
can be only used for the risk estimation for malignant disease.
BRCA1/2 genetic tests were among the first genetic tests
to become widely available, due to high incidence and
high mortality of breast cancer in Western countries.  Ge-
netic testing is performed in order to determine the mo-
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BRCA testing is performed on a peripheral blood sample
due to the fact that we are searching for germ-line mutation
present in all cells in organism. The most appropriate test for
identification of BRCA1/BRCA2 mutations is a complete se-
quence analysis of the entire coding sequence and this remains
the “gold standard” for mutation screening 
34. An ideal situa-
tion is the possibility to test a patient with breast/ovarian can-
cer as the first in the family with clustering of disease. In ad-
dition to the whole BRCA genes sequencing, other options
are possible in certain situations 
34: for BRCA testing of
relatives, when  a specific type of mutation is confirmed in
family member; for limited number of founder mutations in
some populations such as Ashkenazi Jewish women; in 2%–
12% of high-risk patients BRCA alterations are consisted of
large genomic rearrangements and specific techniques such
as multiplex ligation-dependent probe amplification (MLPA)
are indicated.
BRCA1 and BRCA2 testing can result in the finding of
deleterious mutation, with known clinical impact. The pres-
ence of benign polymorphisms, but also of unclassified vari-
ants in both genes was reported. Special problem in deter-
mining genetic susceptibility to breast and/or ovarian cancer
are unclassified variants in BRCA genes 
35. These variants
are missense mutations with uncertain influence on structure
and function of BRCA1/2 protein products that result in their
unknown clinical impact.
Bioethical principles of BRCA testing
Awareness of one’s susceptibility to disease without an
actual possibility of intervention can lead to an unacceptable
use of such information (discrimination or social instrumen-
talization), or might have psychological impact on the person
involved. The question that must be first asked is: Are the
risks connected with the knowledge of susceptibility to ge-
netic disease proportional to the benefits that such knowl-
edge may provide? This problem is vast and involves medi-
cal, psychological, social and ethical dilemmas. These di-
lemmas are common to all predictive medicine, but the most
evident in predictive DNA testing in hereditary breast cancer
due to high risk for breast/ovarian cancer in healthy BRCA
mutation carriers. All available preventive measures (follow-
up, chemoprevention, bilateral prophylactic mastectomy or
oophorectomy) are important but not definitive 
36. The
choice of whether to pursue DNA testing belongs to the indi-
vidual. Respect for the individual’s autonomy is ensured by
obtaining informed consent from that person. It is essential to
offer pre-test counseling to evaluate individual capacity for
autonomous decision-making 
37. Pre-test counseling also
provides view of the risks and benefits, potential treatment as
well as social and ethical implications involved. Genetic in-
formation has implications not only for the patients but also
for their biological kin. Another big problem is to confront
confidential setting between a patient and the physician and
the importance of forwarding that information to biological
kin who can easily be carrier of the same gene alteration.
Appropriate pre-test counseling is finished with a person’s
signing the consent form, where the persons are asked to
state that they fully understand the terms and have had ade-
quate opportunity to ask questions 
37 – our informed consent
has been approved by the Ethics Committee of the Institute. It
is imperative that counseling must be nondirective, allowing a
patient full autonomy in deciding whether to be tested. Pre-test
education should include the following information 
36: de-
scription of the patient’s risk status; explanation of what it
means to have inherited susceptibility to cancer; information
about testing outcomes – results may be positive, negative or
uninformative; appraisal of the risks, benefits and limitations
of genetic testing; discussion on cancer surveillance and
limitations of anticancer therapies; information about the risk
of passing a mutation to children; review of psychological is-
sues related to genetic testing; explanation of alternative to
genetic testing.
In post-test counseling the counselor have to help pa-
tients to understand the results. A patient has also the right to
decide not to be told about test results. Post-test counseling
for mutation carriers must include a full explanation of a
positive result accompanied by a description of surveillance
and options for clinical management. It must be performed
by a genetic counseling team, composed at least of a physi-
cian, genetic counselor, psychologist and registered nurse.
Moral problem lies mostly in concerns how to make mean-
ingful use of the available genetic information and it is nec-
essary to weigh the risks against the harms in concrete cases.
Pathobiology of hereditary breast cancer
Breast cancer is heterogeneous disease in regard to
pathobiological characteristics, prognosis of disease and pre-
dicting response to specific anticancer treatment. Growing
data about different pathobiological characteristics among
BRCA1- and BRCA2-related hereditary breast cancers, as
well as especially BRCA1-related cancer compared to spo-
radic breast cancer with a consequent influence on the course
of the disease, enforce the need for hereditary breast cancer
characterization. Gene expression profiles of breast cancer
have defined specific molecular sub-types with clinical, bio-
logical and therapeutic implications 
38, 39. According to
pathobiological characteristics, the majority of BRCA1-related
cancers can be classified in the group of „triple-negative breast
cancer” (TNBC) since they are characterized with the lack of
expression of steroid receptors (estrogen and progesterone)
and lack of Her-2 receptor overexpression 
40–42. BRCA1-
associated breast cancers are mostly pure differentiated carci-
nomas with ductal histology. About 10% of BRCA1-
associated tumors show atypical medular histology. These
cancers show also high mitotic index, pushing margins and
the presence of necrosis. p53 mutations are more frequent in
BRCA1-related than in sporadic breast cancer 
42. Although
TNBC represents almost the exclusive phenotype in
BRCA1-related breast cancer, it was recently reported that
approximately 10 to 36% of BRCA1-associated breast can-
cers can be ER- positive 
43. It seems that TNBC BRCA1-
related cancer is associated with younger age of onset (50),
while ER+ BRCA1-related cancer occurs in elder mutation
carriers 
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pathologically intermediate between BRCA1-related ER-
breast cancer and ER+ sporadic breast cancer with the possi-
bility that some of ER+ breast cancers in BRCA mutation car-
riers may be incidental 
43. Our previous investigation in Ser-
bian population showed the presence of new BRCA1 muta-
tion, previously not reported, in a patient with ER+ breast can-
cer 
16. It was found in older BRCA mutation carrier with
strong family predisposition supporting an idea about ER+
BRCA1-related cancer as distinct entity of hereditary cancer
rather than possibility that ER+ breast cancer in BRCA1 mu-
tation carriers is not the consequence of BRCA1 dysfunction
and can be considered as sporadic one. BRCA2- associated
breast tumors are more similar to sporadic breast cancer, with
predominant ductal histology, frequent carcinoma in situ and
expression of ER (about 75%) 
41. BRCA1/2 mutations are
common in high-grade serous papillary ovarian carcinomas 
7.
The main question related to pathobiological character-
istics of BRCA- associated cancer is if hereditary form of
disease may have different course of disease in comparison
to sporadic cancer, i.e. be more aggressive. Due to its char-
acteristics, BRCA1- associated breast cancer has more ag-
gressive phenotype and women with BRCA1-associated
breast cancer seem to have worse prognosis of disease than
women with sporadic cancer, while BRCA2-associated
breast cancer is more similar to sporadic one.
Treatment options for hereditary breast/ovarian
cancer
So far, BRCA-related cancer has been treated as spo-
radic cancer – in accordance to classic prognostic parameters
(TNM, grade, histology etc) and breast cancer biomarkers
(steroid and Her-2 receptors, Ki67 etc). BRCA1/2 status as
predictor of various chemotherapy regimens was discussed
in the literature 
44, 45. BRCA deficient tumors was shown to
be more sensitive on platinum derivates regimens 
45. But, it
seems that real revolution will be made with targeted therapy
(PARP inhibitors) for patients with BRCA mutations.
Poly(ADP-ribose) polymerase is nuclear enzyme family in-
volved in base excision repair of single-stranded DNA
breaks.  When activity of PARP is disrupted, DNA replica-
tion can be stopped causing double-strand DNA breaks.
Tumor cells with BRCA1/2 mutations are very sensitive to
the lack of single-stranded breaks repair by PARP inhibition.
By mechanisms of synthetic lethality which confers situation
when there is lethal synergy between two originally non-
lethal cellular events such as inhibition of PARP mediated
repair of single-strand breaks, inducing double-strand breaks
as well, in combination of loss-off-function of BRCA1/2
mediated homologous recombination, new targeted therapy
for BRCA1/2 deficient tumors is constructed 
46. According to
the results of phase II clinical trials with PARP inhibitor
Olaparib (Astra-Zeneca), this approach is very promising for
the treatment of BRCA1/2 mutated breast and ovarian cancer
– complete or partial response was shown in more than 40%
of BRCA1/2 deficient patients 
47, 48.
What can be now recommended for healthy BRCA1/2
mutation carriers? Two main approaches are, so far rec-
ommended: clinical surveillance and prophylactic surgery.
Chemoprevention, as the method also recommended for
medical management of BRCA1/2 mutation carriers, was
shown to be mostly effective for the prevention of contra-
leteral breast cancer in affected BRCA mutation carriers 
49.
In surveillance for breast cancer, breast self-exam, clinical
breast exam as well as radiological exams including mag-
netic resonance imaging in certain time-periods is recom-
mended for healthy BRCA1/2 mutation carriers under the
age of 18 
50, 51. In surveillance for ovarian cancer pelvic ex-
ams, transvaginal ultrasound and CA-125 detection are in-
cluded 
50, 52. However, prophylactic surgery is so far, the
only approach with benefit in risk reduction for hereditary
disease. Bilateral prophlactic mastectomy with breast can-
cer risk reduction greater than 90%, as well as bilateral sal-
pingo-oophorectomy at the age of 35 or after childbearing
is complete with nearly 100% risk reduction for ovarian
cancer, but also up to 68% risk reduction for breast cancer
is recommended for healthy female BRCA1/2 mutation car-
riers 
53, 54.
Conclusion
Genetic testing for BRCA1/2 mutations is not a
screening procedure for general population and is addressed
to a selected part of population eligible according to includ-
ing criteria. BRCA testing, since the presence of BRCA1/2
mutation is one of the best characterized genetic risk factor
for disease, can give reliable result that help in risk estima-
tion for development of breast/ovarian cancer in healthy in-
dividuals. Unfortunately, interpretation of BRCA testing re-
sults may be complex, especially due to posible presence of
unclassified varients in both genes. Furthemore, only inva-
sive prevention strategies such as profilactic surgery demon-
strate risk reduction in healthy BRCA1/2 mutation carriers.
Recent data that BRCA deficient tumors are target for treat-
ment with PARP inhibitor rise possibility of targeted therapy
in the treatment of BRCA-related cancers, but it is posible
that this approach would be in future exploited for cancer
prevention in healthy BRCA carriers.    
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